abstract |
The present invention relates to the glucagon-like peptide-1 (GLP-1) of the incretin hormone and the glucose-dependent insulinotropic polypeptide (GIP), particularly for inhibiting or delaying cartilage destruction in the treatment of osteoarthritis, Or their analogs, particularly the use of analogs resistant to dipeptidyl peptidase IV. [Selection figure] None |